Menu
Report an Issue
Terms of Use
Exit
Prague Classification:
Other Comments:
GUIDELINES WOULD SUGGEST:
Treatment Comparison
Instructions:
To begin your treatment comparison using the TissueCypher® Barrett's Esophagus Assay, please click continue. Your treatment choices will be recorded before and after reviewing the TissueCypher® report. Your treatment choices and the results from all participants to date will be displayed on a summary screen when completed.
Let's begin!
Continue
Provide your answer to the following treatment questions
based on the initial patient data provided
, then click
Continue
:
I will use endoscopic eradication therapy on this patient
*
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
I will reduce the time between surveillance for this patient
*
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
Back
Continue
Based on the
additional information provided by the TissueCypher® Report
, provide your answer to the following treatment questions, then click
Continue
:
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
PATIENT RESULTS: TISSUECYPHER® RISK SCORE AND RISK CLASS
COMPLETE TISSUECYPHER® REPORT
Fullscreen Mode
I will use endoscopic eradication therapy on this patient
*
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
I will reduce the time between surveillance for this patient
*
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
Back
Continue
This field should be left blank